Abstract
The quality of care can be improved by the development and implementation of evidencebased treatment guidelines. Different national guidelines for chronic obstructive pulmonary disease (COPD) exist in Europe and relevant differences may exist among them. This was an evaluation of COPD treatment guidelines published in Europe and Russia in the past 7 years. Each guideline was reviewed in detail and information about the most important aspects of patient diagnosis, risk stratification and pharmacotherapy was extracted following a standardised process. Guidelines were available from the Czech Republic, England and Wales, Finland, France, Germany, Italy, Poland, Portugal, Russia, Spain and Sweden. The treatment goals, criteria for COPD diagnosis, consideration of comorbidities in treatment selection and support for use of long-acting bronchodilators, were similar across treatment guidelines. There were differences in measures used for stratification of disease severity, consideration of patient phenotypes, criteria for the use of inhaled corticosteroids and recommendations for other medications (e.g. theophylline and mucolytics) in addition to bronchodilators. There is generally good agreement on treatment goals, criteria for diagnosis of COPD and use of longacting bronchodilators as the cornerstone of treatment among guidelines for COPD management in Europe and Russia. However, there are differences in the definitions of patient subgroups and other recommended treatments.
| Original language | English |
|---|---|
| Pages (from-to) | 625-637 |
| Number of pages | 13 |
| Journal | European Respiratory Journal |
| Volume | 47 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 1 2016 |
Fingerprint
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
A review of national guidelines for management of COPD in Europe. / Miravitlles, Marc; Vogelmeier, Claus; Roche, Nicolas; Halpin, David; Cardoso, João; Chuchalin, Alexander G.; Kankaanranta, Hannu; Sandström, Thomas; ͆liwiński, Paweł; Zatloukal, Jaromir; Blasi, Francesco.
In: European Respiratory Journal, Vol. 47, No. 2, 01.02.2016, p. 625-637.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A review of national guidelines for management of COPD in Europe
AU - Miravitlles, Marc
AU - Vogelmeier, Claus
AU - Roche, Nicolas
AU - Halpin, David
AU - Cardoso, João
AU - Chuchalin, Alexander G.
AU - Kankaanranta, Hannu
AU - Sandström, Thomas
AU - ͆liwiński, Paweł
AU - Zatloukal, Jaromir
AU - Blasi, Francesco
PY - 2016/2/1
Y1 - 2016/2/1
N2 - The quality of care can be improved by the development and implementation of evidencebased treatment guidelines. Different national guidelines for chronic obstructive pulmonary disease (COPD) exist in Europe and relevant differences may exist among them. This was an evaluation of COPD treatment guidelines published in Europe and Russia in the past 7 years. Each guideline was reviewed in detail and information about the most important aspects of patient diagnosis, risk stratification and pharmacotherapy was extracted following a standardised process. Guidelines were available from the Czech Republic, England and Wales, Finland, France, Germany, Italy, Poland, Portugal, Russia, Spain and Sweden. The treatment goals, criteria for COPD diagnosis, consideration of comorbidities in treatment selection and support for use of long-acting bronchodilators, were similar across treatment guidelines. There were differences in measures used for stratification of disease severity, consideration of patient phenotypes, criteria for the use of inhaled corticosteroids and recommendations for other medications (e.g. theophylline and mucolytics) in addition to bronchodilators. There is generally good agreement on treatment goals, criteria for diagnosis of COPD and use of longacting bronchodilators as the cornerstone of treatment among guidelines for COPD management in Europe and Russia. However, there are differences in the definitions of patient subgroups and other recommended treatments.
AB - The quality of care can be improved by the development and implementation of evidencebased treatment guidelines. Different national guidelines for chronic obstructive pulmonary disease (COPD) exist in Europe and relevant differences may exist among them. This was an evaluation of COPD treatment guidelines published in Europe and Russia in the past 7 years. Each guideline was reviewed in detail and information about the most important aspects of patient diagnosis, risk stratification and pharmacotherapy was extracted following a standardised process. Guidelines were available from the Czech Republic, England and Wales, Finland, France, Germany, Italy, Poland, Portugal, Russia, Spain and Sweden. The treatment goals, criteria for COPD diagnosis, consideration of comorbidities in treatment selection and support for use of long-acting bronchodilators, were similar across treatment guidelines. There were differences in measures used for stratification of disease severity, consideration of patient phenotypes, criteria for the use of inhaled corticosteroids and recommendations for other medications (e.g. theophylline and mucolytics) in addition to bronchodilators. There is generally good agreement on treatment goals, criteria for diagnosis of COPD and use of longacting bronchodilators as the cornerstone of treatment among guidelines for COPD management in Europe and Russia. However, there are differences in the definitions of patient subgroups and other recommended treatments.
UR - http://www.scopus.com/inward/record.url?scp=84958078679&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958078679&partnerID=8YFLogxK
U2 - 10.1183/13993003.01170-2015
DO - 10.1183/13993003.01170-2015
M3 - Article
VL - 47
SP - 625
EP - 637
JO - European Respiratory Journal
JF - European Respiratory Journal
SN - 0903-1936
IS - 2
ER -